Anglade Carole, Breton Mylaine, Simard Frederic, Fitzpatrick Terry, Fitzpatrick Meighen, Bruneau Geneviève, Gaboury Isabelle
Department of Family Medicine and Emergency Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Longueuil, QC, Canada.
Faculty of Medicine and Health Sciences, Department of Community Health, University of Sherbrooke, Longueuil, QC, Canada.
JMIR Res Protoc. 2022 Aug 12;11(8):e34463. doi: 10.2196/34463.
Adherence to care plans is a major issue in health care systems. Improved adherence has several potential benefits such as ensuring treatment effectiveness and control of chronic diseases. There is currently a lack of tools to maximize treatment adherence in an integrated manner, that is, covering multiple aspects of patients' health continuously throughout their medical care. To ensure better adherence, such tools must meet the needs of patients with chronic conditions as well as those of health care professionals. Acknowledging the health issues associated with nonadherence to treatment, an industry-research-clinical partnership aims to adapt a digital platform-facilitating patient-health care professional interactions-to improve therapeutic adherence in patients with chronic illnesses. The platform allows for exchanges between patients and health care professionals to facilitate the timing of medication use or chronic disease management and maximize patient adherence.
This study aims to (1) identify the needs of patients living with a chronic condition and their health professionals concerning their interactions regarding treatment; (2) codevelop an adaptation of an interactive patient-professional platform that meets the needs identified; and (3) then test the platform and document its effects and acceptability in a clinical setting.
The study will use a creative design thinking process based on the needs expressed by users (patients and health professionals) concerning treatment adherence for chronic diseases (eg, diabetes, asthma, high blood pressure, depression and anxiety, chronic obstructive pulmonary disease). A mixed method evaluation research design will be used to develop and evaluate the platform. Qualitative data will be used to assess user needs and acceptability of the platform, and quantitative data will provide the necessary insights to document its effects.
Technological development of the platform has been completed. Recruitment for the first part of Phase 1 started in May 2022. The results of this project to codevelop an interprofessional digital platform to increase therapeutic adherence will be relevant to clinicians and managers seeking contemporary solutions that support patient adherence to treatment for chronic diseases. These results will enable optimal use of the platform and identify areas for improvement in interactive patient-health care professional apps.
The adoption of an interactive digital platform to facilitate effective exchanges between patients and health care professionals in primary care settings could improve adherence to treatment. The platform tested in this project takes a first step in this direction by ensuring that the technological product is developed according to the needs of patients as well as the health professionals who are likely to use it.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/34463.
坚持护理计划是医疗保健系统中的一个主要问题。提高依从性有几个潜在的好处，比如确保治疗效果和控制慢性病。目前缺乏以综合方式最大化治疗依从性的工具，也就是说，在患者整个医疗过程中持续涵盖其健康的多个方面。为确保更好的依从性，此类工具必须满足慢性病患者以及医疗保健专业人员的需求。认识到与不坚持治疗相关的健康问题，一个行业 - 研究 - 临床合作项目旨在调整一个促进患者与医疗保健专业人员互动的数字平台，以提高慢性病患者的治疗依从性。该平台允许患者与医疗保健专业人员进行交流，以促进用药时间安排或慢性病管理，并最大化患者的依从性。
本研究旨在（1）确定慢性病患者及其医疗保健专业人员在治疗互动方面的需求；（2）共同开发一个符合所确定需求的交互式患者 - 专业人员平台的改编版；（3）然后在临床环境中测试该平台，并记录其效果和可接受性。
该研究将采用基于用户（患者和医疗保健专业人员）对慢性病（如糖尿病、哮喘、高血压、抑郁和焦虑、慢性阻塞性肺疾病）治疗依从性所表达需求的创造性设计思维过程。将使用混合方法评估研究设计来开发和评估该平台。定性数据将用于评估用户需求和平台的可接受性，定量数据将提供记录其效果所需的见解。
该平台的技术开发已完成。第一阶段第一部分的招募于2022年5月开始。这个共同开发一个跨专业数字平台以提高治疗依从性的项目结果，将与寻求支持慢性病患者坚持治疗的当代解决方案的临床医生和管理人员相关。这些结果将有助于优化该平台的使用，并确定交互式患者 - 医疗保健专业人员应用程序的改进领域。
采用交互式数字平台以促进初级保健环境中患者与医疗保健专业人员之间的有效交流，可能会提高治疗依从性。本项目中测试的平台朝着这个方向迈出了第一步，通过确保技术产品是根据患者以及可能使用它的医疗保健专业人员需求开发的。
国际注册报告识别号（IRRID）：DERR1 - 10.2196/34463。
